18 received T enanthate 200 mg im every 20 days, 16 received sublingual T cyclodextrin (SLT) at a dose of 2.5 mg three times daily, and 17 received SLT at a dose of 5.0 mg three times daily. The total treatment period was 60 days
Change in scores in single items on a 7-point Likert rating scale measuring anger, alertness, irritability, energy, sadness, tiredness, friendliness, nervousness, and well-being
T replacement led to significant decreases in anger, irritability, sadness, tiredness, and nervousness, and significant improvement in energy, friendliness, and well-being in all subjects as a group. Baseline serum T was positively correlated with friendliness and well-being, and negatively correlated with nervousness, irritability and tiredness. After T replacement these correlations disappeared.
33 hypogonadal men receiving T replacement. 10 eugonadal men receiving T and 19 eugonadal men not administered T
Range: 19–60 yrs Mean: 41.1 yrs (hypogonadal); 33.4 yrs (eugonadal men receiving T); 32. 7 (eugonadal men not administered T)
Eugonadal men received weekly i.m. injections of testosterone enanthate (TE) (200 mg). Hypogonadal men were treated either with 200 mg TE every 20 days or with 2.5 or 5.0 mg sublingual testosterone cyclodextrin 3 times daily
Change in POMS scores after 6 weeks of treatment.
T had positive effects on mood in hypogonadal men, but did not have any effects on mood in eugonadal men.
About 3.9–11.0% of the subjects were <35 yrs, 23.3–36.8% were between 35–49 yrs, 55.1–57.5% were between 50–64 yrs, and 3.9–8.2% were 65+ yrs in the 3 initial treatment groups
In the first 3 months the subjects were randomized to receive 50 mg/day T gel in 5 g gel, 100 mg/day T gel in 10 g gel, or 2 nonscrotal patches delivering 5 mg/day (T patch). In the following 3 months, the subjects were administered 1 of the following treatments: 50 mg/day T gel, 100 g/day T gel, 5.0 mg/day T patch, or 75 mg/day T gel in 7.5 g gel
Sexual function and mood were assessed before clinic visits on day 0 and on days 30, 60, 90, 120, 150, and 180 during gel and patch application
All subjects as a group showed improvement in positive mood. Similarly, the negative mood summary scores showed significant decreases without showing between-group differences.
Testosterone cypionate for 6 weeks in doses rising to 600 mg/wk and placebo for 6 weeks, separated by 6 weeks of no treatment
Differences in YMRS and HAM-D scores
84% of those who received 600 mg/wk of testosterone cypionate exhibited minimal psychiatric effects (YMRS ≤ 10), 12% became mildly hypomanic (YMRS= 10–19), and 4% became markedly hypomanic (YMRS ≥ 20). The HAM-D remained low, with no changes during T administration or withdrawal.
15 eugonadal-men received 200 mg i.m. T enanthate once weekly for 8 weeks, 15 received 200 mg i.m. 0.9% sodium chloride solution weekly for 8 weeks. The hypogonadal group received 200 mg i.m. T enanthate biweekly for 8 weeks
Differences in depression-dejection dimension of the POMS
Significant main effects were found for time, group, and for time x group interaction. Multiple comparisons found that the significant group effect was accounted for by significantly higher levels of total mood disturbance in the hypogonadal group than the eugonadal-treated and eugonadal-placebo groups. However, there was a significant reduction in total mood scores in the hypogonadal group by weeks 1-2 explaining the significant interaction effect.
40 men with prostate cancer treated with androgen blockade therapy
Range: 44–83 yrs; Mean = 72.4 yrs
Androgen blockade therapy (flutamide and leuprolide) for 36 weeks and subsequently followed up for another 18 weeks after discontinuation
Change in BDI scores
BDI scores increased significantly during the active treatment and declined somewhat thereafter. However, the number of people with clinically significant depressive symptoms did not change significantly.
31 healthy adult men with no history of psychiatric illness or substance or anabolic steroid abuse
Range: 18–45 yrs; Mean: yrs
Leuprolide acetate (Lupron) 7.5 mg im every 4 weeks for 3 months. After the first month of Lupron alone, all men received (in addition to Lupron) testosterone enanthate (200 mg i.m.) or placebo every 2 weeks for 1 month each in a crossover design.
Changes in BDI scores
BDI scores significantly increased during Lupron plus placebo compared with baseline and Lupron plus testosterone.
76 healthy men with at least two symptoms on the ADAM, a FT index (FTI) of 0.3–0.5 and TT greater than 8 nmol/L
Range: 60–86 yrs Mean: yrs
80 mg twice daily of testosterone undecanoate—TU (39 subjects) or identical placebo (37 placebo) for 12 months
Differences in GDS scores
From baseline to month-6 there was a significant effects of treatment on depression. No clinically relevant differences on the GDS between the testosterone and placebo group.
Monthly injections of long-acting GnRH agonist to suppress endogenous T production and randomization to one of five doses (25, 50, 125, 300, and 600 mg) of testosterone enanthate weekly for 20 weeks
Changes in HAM-D and YMRS
Baseline depression and mania were not correlated with log FT levels. Changes in mood did not differ by group and were not significantly correlated with FT or TT.
184 men with TT below 12.0 nmol/L or FT below 225 pmol/L, and a diagnosis of the MetS
Range: 35–69 yrs; Mean: yrs
30 weeks with either parenteral testosterone undecanoate (1,000 mg i.m., at baseline, and after 6 and 18 weeks) or placebo injections
Association between BDI and TT. Changes in BDI scores
At baseline, BDI scores significantly correlated with TT (). More improvements in BDI for those treated with T (mean difference versus placebo after 30 weeks: −2.5 points).
